The biopharmaceutical landscape faced a week of sharp contrasts, defined by investor skittishness surrounding oncology efficacy data,...
In the landscape of modern drug discovery, a quiet but profound transformation is underway. What was once...
NEW YORK, NY – As October arrives, the cultural landscape is typically awash in pink ribbons, signaling...
AMMAN, Jordan — In a move to bolster regional stability through health diplomacy, the Director-General of the...
For many individuals, the conclusion of active breast cancer treatment—chemotherapy, radiation, or surgery—is not the finish line,...
NORMAN, OK – In a significant leap forward for cancer research, scientists at the University of Oklahoma...
Endeavor BioMedicines announces pivotal Phase IIb WHISTLE-PF trial results, demonstrating taladegib’s potential to redefine IPF treatment by...
By Douglas Feil, NBCF Chief Program Officer In recent years, glucagon-like peptide-1 (GLP-1) medications have surged in...
NEW YORK, NY — As the world enters the mid-point of Breast Cancer Awareness Month, a global...
NEW YORK CITY – In a powerful demonstration of the intersection between public advocacy and scientific rigor,...
